Loading…
LivaNova PLC is projected to rise to $109.14 by 2027, a +35% move from its current price of $81.05. LIVN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $79.95 | $81.12 | $82.30 | +0.08% |
| Aug 2 | $79.54 | $81.19 | $82.87 | +0.17% |
| Aug 3 | $79.24 | $81.26 | $83.32 | +0.25% |
| Aug 4 | $79.00 | $81.32 | $83.72 | +0.34% |
| Aug 5 | $78.79 | $81.39 | $84.08 | +0.42% |
| Aug 6 | $78.61 | $81.46 | $84.41 | +0.51% |
| Aug 7 | $78.46 | $81.53 | $84.72 | +0.59% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $78.46 | $81.53 | $84.72 | +0.59% |
| Week 2 | $77.67 | $82.01 | $86.59 | +1.19% |
| Week 3 | $77.19 | $82.50 | $88.17 | +1.78% |
| Week 4 | $76.85 | $82.98 | $89.61 | +2.39% |
| Week 5 | $76.60 | $83.48 | $90.96 | +2.99% |
| Week 6 | $76.43 | $83.97 | $92.26 | +3.60% |
| Week 7 | $76.30 | $84.47 | $93.50 | +4.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
LivaNova PLC is a medical technology company that designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products.
The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, other healthcare professionals, hospitals, and other medical institutions and healthcare providers.
LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
LivaNova PLC, LIVN, is a Healthcare company. It is currently priced at $82.56 per share and has a market cap of $4.54B. It holds a rank of 1393 among all traded stocks. The near-term outlook shows a neutral stance in 2026 with the average price at $82.56.
The forecast then projects a bullish trajectory through 2030 and beyond, with the average price rising to $143.59 by 2030 and to $831.21 by 2050, implying substantial upside over the long term.
A major floor 28.9% below — a decisive break under it would weaken the trend.
The nearest floor, 3.5% below — buyers have tended to step in here.
The nearest ceiling, 3.7% above — a clean break opens room to run.
A major ceiling 7.3% above — clearing it would confirm fresh momentum.
Key LIVN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LIVN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $80.67 | Buy | $80.82 | Buy |
| MA 10 | $80.00 | Buy | $80.57 | Buy |
| MA 20 | $81.10 | Sell | $80.42 | Buy |
| MA 50 | $78.65 | Buy | $77.93 | Buy |
| MA 100 | $71.45 | Buy | $73.62 | Buy |
| MA 200 | $66.32 | Buy | $67.59 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.77 | Neutral |
| Stoch RSI (14) | 44.04 | Neutral |
| CCI (20) | -2.27 | Neutral |
| Williams %R (14) | -40.29 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | 2.44 | Buy |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 59.71 | Neutral |
| TRIX (15) | 0.11 | Buy |
| Awesome (5,34) | -0.13 | Sell |
| Ultimate (7,14,28) | 54.17 | Neutral |
| Momentum (10) | -0.74 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 82.02 | Sell |
| ADX (14) | 17.38 | Neutral |
| ATR (14) | 1.04 | Info |
Technical picture for the next 30 days shows bullish sentiment. RSI(14) is 60, indicating mildly overbought conditions. The 50-day simple moving average is $74.86 and the 200-day simple moving average is $64.37. Key near-term levels are support at $71.33 and resistance at $84.03. The 30-day price range runs from a low of $75.79 to a high of $89.93.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $57.59 | $81.05 | $111.94 | 0% | Neutral | |
| $89.48 | $109.14 | $139.09 | +35% | Bullish | |
| $99.88 | $124.14 | $162.55 | +53% | Bullish | |
| $115.47 | $145.74 | $194.95 | +80% | Bullish | |
| $116.99 | $149.67 | $203.84 | +85% | Bullish | |
| $131.30 | $170.03 | $235.25 | +110% | Bullish | |
| $167.71 | $219.65 | $308.24 | +171% | Bullish | |
| $185.45 | $245.46 | $348.94 | +203% | Bullish | |
| $202.75 | $271.03 | $389.92 | +234% | Bullish | |
| $215.88 | $291.32 | $423.79 | +259% | Bullish | |
| $347.86 | $489.64 | $746.56 | +504% | Bullish | |
| $638.93 | $964.60 | $1,576.71 | +10.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $57.59 | $81.05 | $94.47 | +0.00% |
| August 2026 | $73.38 | $85.56 | $101.67 | +5.56% |
| September 2026 | $74.63 | $87.52 | $104.98 | +2.30% |
| October 2026 | $74.11 | $87.31 | $105.51 | -0.24% |
| November 2026 | $75.37 | $89.12 | $108.34 | +2.07% |
| December 2026 | $77.18 | $91.58 | $111.94 | +2.76% |
Click any year to see its month-by-month LIVN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, LIVN could reach as high as $111.94, with a base case around $81.05 and support toward $57.59 — roughly 0% from $81.05. Price action looks broadly range-bound.
Expect LIVN to range from $89.48 to $139.09 through 2027. The $109.14 average target implies a +35% move from current prices. That is up +35% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The LIVN price prediction for 2028 points to an average of $124.14 (low $99.88, high $162.55) — a potential gain of +53% on today's $81.05. Momentum favours further upside here.
In 2029, LIVN is projected to trade between $115.47 and $194.95, averaging $145.74 — a potential gain of +80% from today's $81.05. That is up +17% on the projected 2028 average. Buyers look set to stay in control over this stretch.
LivaNova PLC's 2030 outlook centres on $149.67, within a $116.99 to $203.84 range. That is up +3% on the projected 2029 average. That marks a +85% change versus current levels. Momentum favours further upside here.
By 2031, LIVN could reach as high as $235.25, with a base case around $170.03 and support toward $131.30 — roughly +110% from $81.05. Buyers look set to stay in control over this stretch.
Expect LIVN to range from $167.71 to $308.24 through 2032. The $219.65 average target implies a +171% move from current prices. That is up +29% on the projected 2031 average. Momentum favours further upside here.
The LIVN price prediction for 2033 points to an average of $245.46 (low $185.45, high $348.94) — a potential gain of +203% on today's $81.05. Buyers look set to stay in control over this stretch.
In 2034, LIVN is projected to trade between $202.75 and $389.92, averaging $271.03 — a potential gain of +234% from today's $81.05. That is up +10% on the projected 2033 average. Momentum favours further upside here.
LivaNova PLC's 2035 outlook centres on $291.32, within a $215.88 to $423.79 range. That is up +7% on the projected 2034 average. That marks a +259% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, LIVN could reach as high as $746.56, with a base case around $489.64 and support toward $347.86 — roughly +504% from $81.05. Momentum favours further upside here.
Expect LIVN to range from $638.93 to $1,576.71 through 2050. The $964.60 average target implies a +10.9x move from current prices. That is up +97% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in LIVN today (≈ 12.338063 LIVN) could be worth
$11,901.31
+$10,901.31 (+1090%) by 2050 · US Dollar
Based on the average projected LIVN price of $964.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LIVNwould be worth at today's price.
$1,000 invested in LIVN on Jul 30, 2025 (≈ 22.722109 LIVN) would be worth
$1,841.63
+$841.63 (+84.2%) today · 1.84× · US Dollar
Based on a LIVN entry price of $44.01 vs. today's $81.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $78.61 | $1,031.04 | +3.1% |
| 1 month ago | $82.23 | $985.65 | -1.4% |
| 3 months ago | $61 | $1,328.69 | +32.9% |
| 6 months ago | $65.71 | $1,233.45 | +23.3% |
| 1 year ago | $44.01 | $1,841.63 | +84.2% |
| All time (5.0y) ago | $87.88 | $922.28 | -7.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LIVN forecast.
Our base-case forecast reaches $160.00 around 2031.
Implied market cap at $160.00: $8.79B
The multi-year forecast paints a clearly bullish path from 2027 onward, with a progression of higher averages: 2027 avg $109.87, 2028 avg $125.03, 2029 avg $141.14, 2030 avg $143.59, 2031 avg $164.92, 2032 avg $207.24, 2033 avg $228.15, 2034 avg $253.94, 2035 avg $269.03, 2040 avg $447.69, and 2050 avg $831.21. Corresponding ROI figures rise from 33.1% in 2027 to 906.8% in 2050, with sentiment remaining BULLISH in later years. By 2030 the average price is projected at $143.59 and the ROI at 73.9%.
By 2040 the average price is projected at $447.69 with ROI 442.3%. The forecast therefore indicates sizable upside over the long term, albeit with inherent uncertainty in any projection.
Tap a question to reveal the answer.
Avg $143.59; min $112.17; max $195.72; ROI 73.9%; sentiment BULLISH.
The forecast shows a bullish trajectory from 2027 onward with rising average prices, though the 2026 forecast is neutral (avg $82.56).
Yes. The 2032 forecast shows avg $207.24 and a max of $291.02, indicating potential to exceed $200 by 2032.
Low $75.79 and high $89.93.
Current price $82.56; Market cap $4.54B.
LivaNova PLC Community Discussion
0Share your LivaNova PLC price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.